Voluntis' patented platform works with algorithms that, based on user information, will provide personalized guidance on cancer symptoms and how to mitigate them. In addition, technical teams will be able to monitor and generate more information regarding the patient's condition.
The U.S. Food and Drug Administration (FDA) has approved the Oleena platform that, based on algorithms and user experience, will provide personalized patient dynamics as well as monitoring and generating information for healthcare professionals.
Oleena is software that is part of Class II devices, this means that they are of medium risk and do not use medical substances to generate a diagnosis with the patient.
The platform works directly with the Teraxium Oncologyplatform for digital oncology therapies. It can be used by patients undergoing cancer treatments such as:
- Chemotherapies
- Immunotherapies
- Digital Therapies
The result of the information provided by the application goes according to the symptoms that the user records, adapts to offer personalized guidance on how he can self-control his condition and how to handle his symptoms and instructions on how and when to take the supportive therapies included in his care plan.
"Beyond controlling their symptoms, we believe that empowering patients through digital delivery of personalized, real-time therapeutic interventions offers the opportunity to achieve meaningful clinical and economic results," Pierre Leurent, CEO of Voluntis, said in a statement. "We are delighted to present Oleena, the first digital therapeutic prescription in oncology, to transform the patient experience throughout their cancer journey."
The main impact of this software is to allow patients to play a more active role in their care and control serious symptoms that can complicate treatment. As for the provider, their focus is on improving monitoring through an interface that highlights cases that need more attention and benefit the patient care team.
"Digital therapeutics like Oleena represent a critical addition to managing symptoms at the level of oncology practices," Dr. Arvind Dasari of the University of Texas MD Anderson Cancer Center said in a statement provided by Voluntis. "Simple language and easy-to-use interfaces simplify patient self-management. Integrated clinical algorithms enable automated, proactive intervention that helps healthcare teams, both in terms of customization and standardization."
Oleena's algorithms completely rethink users' experience of information obtained through applications to understand and be able to better track treatments to fight cancer.
The use of Oleena is only allowed with a prescription, but there are other tools focused on monitoring the symptoms of cancer patients who have free use.
MOBI HEALTH NEWS
VOLUNTIS
ABOUT FDA AND CLASS DEVICES
https://sites.jamanetwork.com/spanish-patient-pages/2014/hoja-para-el-paciente-de-jama-140122.pdf
